Market news

CAMBRIDGE, Mass., September 15, 2026--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application covering novel compounds within its EVM401 Series of drug candidates. The EVM401 Series comprises proprietary, non-hal

CAMBRIDGE, Mass., September 01, 2026--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that Joseph Tucker, Ph.D., CEO of Enveric will deliver a virtual presentation at the H.C. Wainwright 28th Annual Global Investment Conference, which is being held September 14-16, 2026, in New York City.

CAMBRIDGE, Mass., August 14, 2026--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2026, and provided a comprehensive business update.

Enveric Biosciences reports new preclinical data supporting the non-hallucinogenic profile of its lead psychiatric drug candidate, EB-003.

CAMBRIDGE, Mass., August 05, 2026--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced new preclinical data that further supports the growing body of evidence reinforcing the non-hallucinogenic profile of its lead candidate, EB-003.

CAMBRIDGE, Mass., July 28, 2026--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today welcomed the U.S. Food and Drug Administration's (FDA) recent release of finalized guidance for clinical investigations of psychedelic and psychedelic-inspired therapeutics.